menu
    • menu
    [{"orgOrder":0,"company":"TB Alliance","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Linezolid","moa":"||Adenosine triphosphatase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TB Alliance","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TB Alliance \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TB Alliance \/ Undisclosed"},{"orgOrder":0,"company":"TB Alliance","sponsor":"Australian Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"Linezolid","moa":"||Adenosine triphosphatase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TB Alliance","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"TB Alliance \/ Australian Government","highestDevelopmentStatusID":"8","companyTruncated":"TB Alliance \/ Australian Government"},{"orgOrder":0,"company":"Mahidol University","sponsor":"Siam Pharmaceutical Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"THAILAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Linezolid","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Mahidol University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mahidol University \/ Siam Pharmaceutical Ltd.","highestDevelopmentStatusID":"11","companyTruncated":"Mahidol University \/ Siam Pharmaceutical Ltd."},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Ministry of Health & Welfare, Korea | SMG-SNU Boramae Medical Center | Seoul National University Bundang Hospital | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Linezolid","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Ministry of Health & Welfare, Korea | SMG-SNU Boramae Medical Center | Seoul National University Bundang Hospital | Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Seoul National University Hospital \/ Ministry of Health & Welfare, Korea | SMG-SNU Boramae Medical Center | Seoul National University Bundang Hospital | Pfizer Inc"},{"orgOrder":0,"company":"University Ghent","sponsor":"University Hospital Ghent | Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Linezolid","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"University Ghent","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University Ghent \/ University Hospital Ghent | Pfizer Inc","highestDevelopmentStatusID":"11","companyTruncated":"University Ghent \/ University Hospital Ghent | Pfizer Inc"},{"orgOrder":0,"company":"London School of Hygiene & Tropical Medicine","sponsor":"University College Dublin | University of Stellenbosch | Malawi Liverpool Wellcome Programme | University of Sydney | Murdoch Childrens Research Institute | MRC CTU at UCL | PHPT\/AMS Laboratory","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Linezolid","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"London School of Hygiene & Tropical Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"London School of Hygiene & Tropical Medicine \/ University College Dublin | University of Stellenbosch | Malawi Liverpool Wellcome Programme | University of Sydney | Murdoch Childrens Research Institute | MRC CTU at UCL | PHPT\/AMS Laboratory","highestDevelopmentStatusID":"8","companyTruncated":"London School of Hygiene & Tropical Medicine \/ University College Dublin | University of Stellenbosch | Malawi Liverpool Wellcome Programme | University of Sydney | Murdoch Childrens Research Institute | MRC CTU at UCL | PHPT\/AMS Laboratory"},{"orgOrder":0,"company":"Persica Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Linezolid","moa":"Bacterial 70S ribosome","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Persica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Persica Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Persica Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Persica Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Linezolid","moa":"Bacterial 70S ribosome","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Persica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Persica Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Persica Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Persica Pharmaceuticals","sponsor":"Micron Research Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Linezolid","moa":"Bacterial 70S ribosome","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Persica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Persica Pharmaceuticals \/ Micron Research Ltd","highestDevelopmentStatusID":"7","companyTruncated":"Persica Pharmaceuticals \/ Micron Research Ltd"},{"orgOrder":0,"company":"University of Chicago","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Linezolid","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Chicago","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Chicago \/ Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"University of Chicago \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Linezolid","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Linezolid","moa":"Bacterial 70S ribosome","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cefiderocol sulfate tosylate","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cefiderocol sulfate tosylate","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shionogi \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shionogi \/ Undisclosed"},{"orgOrder":0,"company":"TB Alliance","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Partnership","leadProduct":"Pretomanid","moa":"||mycolic acid inhibitors","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"TB Alliance","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TB Alliance \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"TB Alliance \/ Lupin Ltd"},{"orgOrder":0,"company":"TB Alliance","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Pretomanid","moa":"||mycolic acid inhibitors","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"TB Alliance","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"TB Alliance \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"TB Alliance \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Linosept

    Menu

    Linosept

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            London School of Hygiene & Tropical Medicine

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            London School of Hygiene & Tropical Medicine

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Linezolid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : University College Dublin | University of Stellenbosch | Malawi Liverpool Wellcome Programme | University of Sydney | Murdoch Childrens Research Institute | MRC CTU at UCL | PHPT/AMS Laboratory

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comprehensive Ambulatory Antibiotics for the Treatment of Congenital Syphilis

                            Details : Linezolid is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Syphilis, Congenital.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 10, 2025

                            Lead Product(s) : Linezolid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : University College Dublin | University of Stellenbosch | Malawi Liverpool Wellcome Programme | University of Sydney | Murdoch Childrens Research Institute | MRC CTU at UCL | PHPT/AMS Laboratory

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Persica Pharmaceuticals

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Persica Pharmaceuticals

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Linezolid

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Persica’s PP353 Phase 1b Shows Promise for Chronic Low Back Pain

                            Details : PP353 is an antibiotic formulation designed for intradiscal injection under image guidance. It is being evaluated for the treatment of chronic lower back pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 05, 2025

                            Lead Product(s) : Linezolid

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            TB Alliance

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            TB Alliance

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TBAJ-876,Linezolid,Pretomanid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Australian Government

                            Deal Size : $11.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Australian Government Grants TB Alliance for Drug-Resistant TB Research

                            Details : Funding supports the NC-009 Pan-Phase 2 trial of TBAJ-876 combined with pretomanid and linezolid for treating drug-sensitive and resistant tuberculosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            March 24, 2024

                            Lead Product(s) : TBAJ-876,Linezolid,Pretomanid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Australian Government

                            Deal Size : $11.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Persica Pharmaceuticals

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Persica Pharmaceuticals

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Linezolid

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Persica Pharmaceuticals Completes Recruitment for Chronic Pain Trial

                            Details : PP353 is an antibiotic formulation for intradiscal injection, under evaluation for chronic lower back pain treatment by delivering targeted antibiotic exposure.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 07, 2024

                            Lead Product(s) : Linezolid

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            TB Alliance

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            TB Alliance

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TBAJ-876,Linezolid,Pretomanid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TB Alliance Launches Five-Country Phase 2 Clinical Trial Evaluating Next-Generation TB Drug

                            Details : TBAJ-876 is a diarylquinoline antibiotic that targets a key enzyme of TB bacteria involved in energy production, it is being evaluated in combination with pretomanid and linezolid, for the treatment for both drug-sensitive and drug-resistant TB.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 16, 2023

                            Lead Product(s) : TBAJ-876,Linezolid,Pretomanid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            TB Alliance

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            TB Alliance

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pretomanid,Bedaquiline,Linezolid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Lupin Ltd

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            TB Alliance and Lupin Announce Commercial Partnership for New Therapy for Highly Drug-Resistant TB

                            Details : Lupin intends to commercialize the anti-tuberculosis (TB) medicine, Pretomanid, in approximately 140 countries and territories, including many of the highest TB burden countries around the world.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            September 06, 2021

                            Lead Product(s) : Pretomanid,Bedaquiline,Linezolid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Lupin Ltd

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Persica Pharmaceuticals

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Persica Pharmaceuticals

                            United Kingdom arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Linezolid

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Micron Research Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Persica Pharmaceuticals has Completed the First Stage of Its Clinical Trial on Unique Injectable PP353, To Tre...

                            Details : PP353 is a sustained release formulation of an antibiotic to treat the chronic disc infection, which is designed for intradiscal injection under image guidance.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 19, 2021

                            Lead Product(s) : Linezolid

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Micron Research Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Shionogi

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Shionogi

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cefiderocol sulfate tosylate,Linezolid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Shionogi Announces FDA Approval of Fetroja® for Hospital-Acquired Bacterial Pneumonia AND Ventilator-Associat...

                            Details : U.S.FDA has approved a supplemental New Drug Application for FETROJA® (cefiderocol) for the treatment of patients 18 years of age or older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).

                            Product Name : Fetroja

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 28, 2020

                            Lead Product(s) : Cefiderocol sulfate tosylate,Linezolid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            TB Alliance

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            TB Alliance

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pretomanid,Bedaquiline,Linezolid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TB Alliance Announces European Commission Authorisation of New Treatment for Highly Drug-Resistant Tuberculosi...

                            Details : The new drug was authorised as part of a three-drug, six month, all-oral regimen for the treatment of adults with extensively drug-resistant TB (XDR-TB) or multidrug-resistant TB (MDR-TB) who are treatment-intolerant or non-responsive.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            August 03, 2020

                            Lead Product(s) : Pretomanid,Bedaquiline,Linezolid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Shionogi

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Shionogi

                            Japan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cefiderocol sulfate tosylate,Linezolid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Accepts Shionogi’s sNDA with Priority Review for FETROJA® for Hospital-Acquired Pneumonia and Ventilato...

                            Details : FDA has accepted the company’s supplemental New Drug Application (sNDA) for FETROJA® (cefiderocol) and granted Priority Review designation with a Prescription Drug User Fee Act (PDUFA) date of September 27, 2020.

                            Product Name : Fetroja

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 01, 2020

                            Lead Product(s) : Cefiderocol sulfate tosylate,Linezolid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth